UBS Group
MNTA

UBS Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

UBS Group’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-500
Closed -$6K – 9641
2014
Q4 		$6K Buy
+500
New +$5.71K ﹤0.01% 8882

UBS Group's MNTA Position: Q4 2020 in Review

UBS Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 2,378 shares — an estimated $125K sold.

UBS Group first reported a position in MNTA in Q4 2014 and held it in 24 quarters. The position peaked at $1.64M in Q1 2018. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.

  • UBS Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 2,378 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $125K.
  • UBS Group first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 24 quarters.
  • UBS Group's Momenta Pharmaceuticals, Inc. position peaked at $1.64M in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.